Weight-Loss drug tirzepatide may help keep heart rhythm steady after ablation

NCT ID NCT07715929

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This trial tests whether adding tirzepatide (Mounjaro) to a structured lifestyle program reduces the return of atrial fibrillation within a year after catheter ablation in obese patients. About 710 participants with symptomatic AF and a BMI of 28 or higher (or 24 with other risk factors) will receive either tirzepatide injections plus lifestyle changes or lifestyle changes alone. The main goal is to see if the drug lowers the rate of AF, atrial flutter, or atrial tachycardia episodes lasting 30 seconds or more.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tirzepatide (Mounjaro), a once-weekly injection that targets two gut hormones to promote weight loss and improve metabolism
What this could lead to
If successful, this could offer a new way to prevent atrial fibrillation from coming back after ablation in people with obesity, combining weight-loss medication with lifestyle changes.
What could go wrong
This is a Phase 4 trial, so the drug is already approved for weight loss, but its effect on heart rhythm after ablation is unproven. Side effects like nausea or rare pancreatitis are possible, and the open-label design may introduce bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.